C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $161,091 | $101,539 | $113,333 | $254,182 |
| - Cash | $58,809 | $78,157 | $51,293 | $55,499 |
| + Debt | $61,463 | $62,923 | $64,366 | $65,756 |
| Enterprise Value | $163,745 | $86,305 | $126,406 | $264,439 |
| Revenue | $11,230 | $6,463 | $7,238 | $5,177 |
| % Growth | 73.8% | -10.7% | 39.8% | – |
| Gross Profit | $11,230 | $6,463 | $7,238 | $3,411 |
| % Margin | 100% | 100% | 100% | 65.9% |
| EBITDA | -$31,706 | -$27,886 | -$28,708 | -$32,676 |
| % Margin | -282.3% | -431.5% | -396.6% | -631.2% |
| Net Income | -$32,166 | -$26,020 | -$26,322 | -$34,573 |
| % Margin | -286.4% | -402.6% | -363.7% | -667.8% |
| EPS Diluted | -0.44 | -0.37 | -0.37 | -0.49 |
| % Growth | -18.9% | 0% | 24.5% | – |
| Operating Cash Flow | -$31,207 | -$12,057 | -$33,285 | -$17,932 |
| Capital Expenditures | -$411 | -$185 | $0 | $4 |
| Free Cash Flow | -$31,618 | -$12,242 | -$33,285 | -$17,928 |